Trial
NCT04060888
A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus
Phase IIIWITHDRAWNEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Lupus Erythematosus, Systemic
Intervention
Ustekinumab (approximately 6 mg/kg)
Why stopped
Pre-planned IA (global study) showed lack of efficacy in this indication. No new safety signals observed, findings consistent with known profile.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-03